Arcutis Biotherapeutics (ARQT) Financials

$14.14 +0.16 (+1.14%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$14.22 +0.08 (+0.59%)

As of 04:13 AM Eastern

Annual Income Statements for Arcutis Biotherapeutics

This table shows Arcutis Biotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Income / (Loss) Attributable to Common Shareholders	-140	-262	-311	-206	-136	-42	-19
Consolidated Net Income / (Loss)	-140	-262	-311	-206	-136	-42	-19
Net Income / (Loss) Continuing Operations	-140	-262	-311	-206	-136	-42	-19
Total Pre-Tax Income	-156	-259	-311	-206	-136	-42	-19
Total Operating Income	-128	-241	-302	-207	-137	-43	-20
Total Gross Profit	177	55	2.93	0.00	0.00	0.00	0.00
Total Revenue	197	60	3.69	0.00	0.00	0.00	0.00
Operating Revenue	197	60	3.69	0.00	0.00	-	-
Total Cost of Revenue	19	4.99	0.75	0.00	0.00	0.00	0.00
Operating Cost of Revenue	19	4.99	0.75	0.00	0.00	-	-
Total Operating Expenses	306	296	305	207	137	43	20
Selling, General & Admin Expense	229	185	122	61	21	6.61	1.80
Research & Development Expense	76	111	182	146	115	37	18
Total Other Income / (Expense), net	-27	-18	-9.83	0.17	0.97	1.14	0.48
Interest Expense	27	30	16	0.00	0.00	-	-
Income Tax Expense	0.65	3.11	0.00	-	-	-	-
Other Gains / (Losses), net	16	-	-	-	-	-	-
Basic Earnings per Share	($1.16)	($3.78)	($5.66)	($4.18)	($3.80)	($22.78)	($15.53)
Weighted Average Basic Shares Outstanding	120.96M	69.31M	55.03M	49.41M	35.67M	1.84M	1.24M
Diluted Earnings per Share	($1.16)	($3.78)	($5.66)	($4.18)	($3.80)	($22.78)	($15.53)
Weighted Average Diluted Shares Outstanding	120.96M	69.31M	55.03M	49.41M	35.67M	1.84M	1.24M
Weighted Average Basic & Diluted Shares Outstanding	118.64M	-	61.08M	50.38M	35.67M	1.84M	1.24M

This table shows Arcutis Biotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-25	-11	-42	-52	-35	-66	-45	-71	-80	-72	-108
Consolidated Net Income / (Loss)	-25	-11	-42	-52	-35	-66	-45	-71	-80	-72	-108
Net Income / (Loss) Continuing Operations	-25	-11	-42	-52	-35	-66	-45	-71	-80	-72	-108
Total Pre-Tax Income	-25	-27	-42	-52	-35	-66	-42	-71	-80	-72	-108
Total Operating Income	-25	-7.63	-39	-50	-32	-61	-37	-67	-76	-68	-105
Total Gross Profit	57	64	39	27	46	11	37	4.41	2.00	2.48	0.46
Total Revenue	66	71	45	31	50	14	38	5.19	2.78	2.96	0.73
Operating Revenue	66	71	45	31	50	14	38	5.19	2.78	-	0.73
Total Cost of Revenue	8.83	6.91	5.50	3.46	3.26	2.25	1.18	0.78	0.78	0.49	0.27
Operating Cost of Revenue	8.83	6.91	5.50	3.46	3.26	2.25	1.18	0.78	0.78	-	0.27
Total Operating Expenses	82	72	78	77	78	72	74	71	78	71	105
Selling, General & Admin Expense	64	58	59	58	55	49	48	46	43	37	35
Research & Development Expense	18	14	20	19	23	24	26	25	35	34	70
Total Other Income / (Expense), net	-0.25	-19	-2.47	-2.26	-3.44	-5.03	-4.84	-4.23	-3.84	-3.60	-2.96
Interest Expense	2.98	5.55	6.65	7.48	7.48	7.76	7.56	7.35	7.04	6.92	4.90
Other Income / (Expense), net	2.73	-	4.18	5.23	4.04	2.74	2.72	3.12	3.21	3.32	1.94
Income Tax Expense	0.28	0.32	0.00	0.00	0.32	0.09	3.02	0.00	0.00	-	0.00
Basic Earnings per Share	($0.20)	($0.09)	($0.33)	($0.42)	($0.32)	($0.58)	($0.73)	($1.16)	($1.31)	($1.19)	($1.89)
Weighted Average Basic Shares Outstanding	126.04M	120.96M	124.30M	123.48M	111.05M	69.31M	61.73M	61.43M	61.17M	55.03M	57.09M
Diluted Earnings per Share	($0.20)	($0.09)	($0.33)	($0.42)	($0.32)	($0.58)	($0.73)	($1.16)	($1.31)	($1.19)	($1.89)
Weighted Average Diluted Shares Outstanding	126.04M	120.96M	124.30M	123.48M	111.05M	69.31M	61.73M	61.43M	61.17M	55.03M	57.09M
Weighted Average Basic & Diluted Shares Outstanding	119.20M	118.64M	117.04M	116.89M	115.76M	0.00	94.38M	61.65M	61.42M	61.08M	60.93M

This table details how cash moves in and out of Arcutis Biotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Change in Cash & Equivalents	-17	34	-43	31	3.29	24	36
Net Cash From Operating Activities	-112	-247	-258	-175	-113	-43	-14
Net Cash From Continuing Operating Activities	-112	-247	-258	-175	-113	-43	-14
Net Income / (Loss) Continuing Operations	-140	-262	-311	-206	-136	-42	-19
Consolidated Net Income / (Loss)	-140	-262	-311	-206	-136	-42	-19
Depreciation Expense	0.64	0.77	0.62	0.45	0.12	0.07	0.00
Amortization Expense	-4.94	-6.24	-1.94	3.45	0.07	-0.35	-0.01
Non-Cash Adjustments To Reconcile Net Income	47	44	65	24	8.32	0.95	3.08
Changes in Operating Assets and Liabilities, net	-15	-24	-10	3.62	14	-1.51	2.11
Net Cash From Investing Activities	29	180	-87	-76	-182	-26	-12
Net Cash From Continuing Investing Activities	29	180	-87	-76	-182	-26	-12
Purchase of Property, Plant & Equipment	-0.14	-0.43	-0.33	-1.00	-0.32	-0.30	0.00
Acquisitions	-5.00	0.00	-23	0.00	0.00	-	-
Purchase of Investments	-255	-226	-415	-293	-279	-61	-12
Sale and/or Maturity of Investments	289	407	351	218	98	35	0.00
Net Cash From Financing Activities	66	101	302	282	298	93	62
Net Cash From Continuing Financing Activities	66	101	302	282	298	93	62
Repayment of Debt	-100	0.00	-2.19	-1.64	0.00	-1.40	0.00
Issuance of Debt	0.00	0.00	125	74	0.00	0.00	-
Issuance of Common Equity	163	100	178	208	298	0.00	0.00
Other Financing Activities, net	2.81	1.25	1.02	1.27	0.53	0.27	0.39
Effect of Exchange Rate Changes	-0.24	-0.05	0.00	-	-	-	-
Cash Interest Paid	22	25	13	0.14	0.00	0.00	-

This table details how cash moves in and out of Arcutis Biotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-18	-64	51	-106	101	-19	2.36	24	27	-28	20
Net Cash From Operating Activities	-30	-0.75	-35	-45	-32	-56	-44	-66	-80	-71	-68
Net Cash From Continuing Operating Activities	-30	-0.75	-35	-44	-32	-56	-44	-66	-80	-71	-68
Net Income / (Loss) Continuing Operations	-25	-11	-42	-52	-35	-66	-45	-71	-80	-72	-108
Consolidated Net Income / (Loss)	-25	-11	-42	-52	-35	-66	-45	-71	-80	-72	-108
Depreciation Expense	0.15	0.15	0.16	0.16	0.17	0.20	0.20	0.20	0.18	0.16	0.16
Amortization Expense	2.12	-0.78	-0.42	-2.20	-1.54	-1.29	-1.35	-1.64	-1.97	-2.16	-0.68
Non-Cash Adjustments To Reconcile Net Income	10	12	10	14	11	11	11	12	11	10	39
Changes in Operating Assets and Liabilities, net	-18	-1.57	-3.80	-4.27	-5.44	0.41	-9.18	-5.73	-9.01	-7.41	1.23
Net Cash From Investing Activities	12	35	85	-62	-29	-62	46	89	108	42	-197
Net Cash From Continuing Investing Activities	12	35	85	-62	-29	-62	46	89	108	42	-197
Purchase of Property, Plant & Equipment	-0.61	-	-0.14	-	0.00	-0.01	-0.06	-0.28	-0.08	-0.12	-0.01
Purchase of Investments	-56	-17	-5.69	-126	-106	-118	-22	-46	-40	-38	-242
Sale and/or Maturity of Investments	68	57	91	64	77	56	68	135	148	80	67
Net Cash From Financing Activities	0.40	-97	0.39	1.46	162	99	0.87	1.07	0.10	0.96	285
Net Cash From Continuing Financing Activities	0.40	-97	0.39	1.46	162	99	0.87	1.07	0.10	0.96	285
Issuance of Common Equity	0.00	1.06	-	0.65	162	99	-	0.99	0.00	0.95	162
Other Financing Activities, net	0.40	1.53	0.39	0.81	0.08	0.21	0.87	0.07	0.10	0.02	0.58
Effect of Exchange Rate Changes	0.00	-0.23	0.10	-0.03	-0.07	0.07	-0.08	0.01	-0.05	-	-
Cash Interest Paid	2.57	2.96	6.23	6.51	6.51	6.58	6.55	6.31	6.00	5.71	3.93

This table presents Arcutis Biotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Total Assets	349	341	449	408	298	107
Total Current Assets	336	330	437	403	293	106
Cash & Equivalents	71	88	54	96	65	63
Restricted Cash	0.62	0.93	1.23	1.54	1.54	0.00
Short-Term Investments	157	183	356	291	219	38
Accounts Receivable	73	26	8.46	0.00	-	-
Inventories, net	15	13	7.51	0.00	-	-
Prepaid Expenses	20	19	11	14	6.84	5.21
Plant, Property, & Equipment, net	1.04	1.54	1.88	2.26	2.02	0.23
Total Noncurrent Assets	12	9.40	9.99	3.12	3.43	0.31
Intangible Assets	9.48	6.44	7.19	0.00	-	-
Other Noncurrent Operating Assets	2.55	2.96	2.80	3.12	3.43	0.31
Total Liabilities & Shareholders' Equity	349	341	449	408	298	107
Total Liabilities	191	253	240	110	28	5.55
Total Current Liabilities	81	47	38	33	23	5.24
Accounts Payable	14	12	8.83	7.35	7.14	1.41
Accrued Expenses	66	34	28	26	15	3.65
Other Current Liabilities	0.82	0.74	0.66	0.43	0.00	0.18
Total Noncurrent Liabilities	110	206	202	77	5.05	0.31
Long-Term Debt	107	202	198	72	-	-
Other Noncurrent Operating Liabilities	3.13	4.23	4.12	4.80	5.05	0.31
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	158	89	210	298	271	-65
Total Preferred & Common Equity	158	89	210	298	271	-65
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	158	89	210	298	271	-65
Common Stock	1,279	1,071	930	706	473	1.24
Retained Earnings	-1,122	-982	-720	-408	-202	-66
Accumulated Other Comprehensive Income / (Loss)	-0.01	0.00	-1.09	-0.26	-0.00	-0.00

This table presents Arcutis Biotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	344	437	445	479	293	321	379	509
Total Current Assets	324	424	435	468	282	309	368	497
Cash & Equivalents	53	135	84	190	107	105	81	82
Restricted Cash	0.62	0.62	0.62	0.62	0.93	0.93	0.93	1.23
Short-Term Investments	145	196	278	214	120	164	251	395
Accounts Receivable	85	60	43	37	19	17	13	2.43
Inventories, net	17	14	14	13	14	10	8.55	4.31
Prepaid Expenses	23	18	14	13	20	12	13	12
Plant, Property, & Equipment, net	1.50	1.19	1.35	1.37	1.74	1.87	2.07	1.94
Total Noncurrent Assets	19	12	8.82	9.11	9.68	9.95	9.71	10
Intangible Assets	17	9.79	6.06	6.25	6.63	6.81	7.00	7.38
Other Noncurrent Operating Assets	2.44	2.66	2.76	2.86	3.05	3.14	2.71	2.88
Total Liabilities & Shareholders' Equity	344	437	445	479	293	321	379	509
Total Liabilities	201	281	258	254	246	240	240	238
Total Current Liabilities	91	172	51	47	42	37	37	37
Accounts Payable	25	19	7.94	13	13	17	12	8.67
Accrued Expenses	66	53	43	34	28	19	24	28
Other Current Liabilities	0.84	0.80	0.78	0.76	0.72	0.70	0.68	0.64
Total Noncurrent Liabilities	110	108	207	206	204	204	203	201
Long-Term Debt	108	105	204	203	201	200	199	197
Other Noncurrent Operating Liabilities	2.70	3.19	3.17	3.49	3.57	3.76	3.94	4.29
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	143	157	186	225	47	81	140	271
Total Preferred & Common Equity	143	157	186	225	47	81	140	271
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	143	157	186	225	47	81	140	271
Common Stock	1,290	1,267	1,256	1,242	963	952	940	920
Retained Earnings	-1,147	-1,111	-1,070	-1,017	-916	-871	-800	-648
Accumulated Other Comprehensive Income / (Loss)	-0.14	0.53	-0.29	-0.13	-0.18	-0.29	-0.41	-1.60

This table displays calculated financial ratios and metrics derived from Arcutis Biotherapeutics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	229.74%	1,517.09%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	43.48%	20.98%	-46.77%	-49.43%	-220.43%	-119.43%	0.00%
EBIT Growth	44.01%	22.48%	-43.35%	-52.09%	-223.07%	-118.10%	0.00%
NOPAT Growth	46.75%	20.07%	-46.05%	-51.14%	-216.81%	-118.56%	0.00%
Net Income Growth	46.58%	15.83%	-50.93%	-52.09%	-223.07%	-118.10%	0.00%
EPS Growth	69.31%	33.22%	-35.41%	-10.00%	83.32%	-46.68%	0.00%
Operating Cash Flow Growth	54.60%	4.14%	-47.58%	-54.49%	-163.87%	-204.13%	0.00%
Free Cash Flow Firm Growth	42.94%	16.05%	-60.05%	-76.49%	-163.55%	0.00%	0.00%
Invested Capital Growth	104.59%	609.07%	81.30%	-20.91%	-7,897.97%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	21.54%	408.41%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	3.13%	1.07%	-22.12%	-18.44%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	2.83%	2.06%	-22.05%	-18.81%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	2.92%	0.94%	-21.98%	-18.23%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	2.14%	-0.22%	-22.05%	-18.81%	0.00%	0.00%
EPS Q/Q Growth	0.00%	13.90%	4.23%	-21.51%	60.21%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	5.66%	-8.12%	-12.31%	-16.22%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-921.49%	6.89%	-8.62%	-9.29%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	20.29%	-9.16%	67.45%	-219.31%	7.69%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	90.27%	91.63%	79.54%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-67.52%	-393.89%	-8,060.91%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-65.33%	-404.49%	-8,183.04%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-65.33%	-384.72%	-8,025.12%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-71.25%	-439.79%	-8,449.76%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	90.02%	101.20%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	121.16%	112.96%	105.29%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-333.80%	-2,375.88%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-281.64%	-2,310.14%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	220.04%	2,200.09%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-113.76%	-175.79%	-122.80%	-72.62%	-72.93%	-41.39%	0.00%
Cash Return on Invested Capital (CROIC)	-402.47%	-1,074.23%	0.00%	0.00%	0.00%	-30,852.18%	0.00%
Operating Return on Assets (OROA)	-37.20%	-58.01%	-69.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-40.58%	-66.31%	-72.65%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-113.76%	-175.79%	-122.80%	-72.62%	-40.30%	26.53%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-88.89%	-295.65%	-148.61%	-69.32%	-50.14%	64.58%	0.00%
Net Operating Profit after Tax (NOPAT)	-90	-169	-211	-145	-96	-30	-14
NOPAT Margin	-45.73%	-283.14%	-5,728.13%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-52.15%	-65.74%	-37.91%	-20.52%	-20.67%	-23.31%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-33.95%	-58.10%	-51.83%	-	-	-	-
Cost of Revenue to Revenue	9.73%	8.37%	20.46%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	116.71%	310.61%	3,313.19%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	38.88%	185.51%	4,949.40%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	155.60%	496.12%	8,262.59%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-128	-229	-296	-206	-136	-42	-19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-133	-235	-297	-202	-135	-42	-19
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	10.35	3.44	4.30	3.50	4.54	0.00	0.00
Price to Tangible Book Value (P/TBV)	11.01	3.71	4.46	3.50	4.54	0.00	0.00
Price to Revenue (P/Rev)	8.30	5.11	244.64	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	41.72	13.23	0.00	0.00	0.00	1,140.11	0.00
Enterprise Value to Revenue (EV/Rev)	7.68	3.92	186.84	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.68	2.28	0.94	0.24	0.00	0.00	0.00
Long-Term Debt to Equity	0.68	2.28	0.94	0.24	0.00	0.00	0.00
Financial Leverage	-0.78	-0.95	-1.04	-1.06	-1.04	-1.00	0.00
Leverage Ratio	2.80	2.65	1.69	1.24	1.09	1.05	0.00
Compound Leverage Factor	3.40	2.99	1.78	1.24	1.09	1.05	0.00
Debt to Total Capital	40.49%	69.47%	48.55%	19.55%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	40.49%	69.47%	48.55%	19.55%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	164.09%	0.00%
Common Equity to Total Capital	59.51%	30.53%	51.45%	80.45%	100.00%	-64.09%	0.00%
Debt to EBITDA	-0.81	-0.86	-0.67	-0.36	0.00	0.00	0.00
Net Debt to EBITDA	0.91	0.30	0.72	1.56	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.81	-0.86	-0.67	-0.36	0.00	0.00	0.00
Debt to NOPAT	-1.19	-1.20	-0.94	-0.50	0.00	0.00	0.00
Net Debt to NOPAT	1.35	0.42	1.01	2.19	0.00	0.00	0.00
Long-Term Debt to NOPAT	-1.19	-1.20	-0.94	-0.50	0.00	0.00	0.00
Altman Z-Score	0.84	-4.35	-1.08	3.68	25.28	16.20	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	44.75%	164.09%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	4.15	7.08	11.57	12.09	12.96	20.33	0.00
Quick Ratio	3.72	6.38	11.06	11.61	12.58	19.34	0.00
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-108	-190	-226	-141	-80	-30	0.00
Operating Cash Flow to CapEx	-78,432.17%	-57,723.60%	-77,391.89%	-17,550.45%	-35,212.77%	-14,520.68%	0.00%
Free Cash Flow to Firm to Interest Expense	-3.99	-6.39	-14.45	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-4.13	-8.32	-16.47	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-4.13	-8.33	-16.49	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.57	0.15	0.01	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	3.98	3.48	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	1.38	0.48	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	152.36	34.86	1.78	0.00	0.00	0.00	0.00
Accounts Payable Turnover	1.46	0.48	0.09	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	91.81	104.91	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	263.90	755.62	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	250.09	761.87	3,916.25	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	105.62	98.65	-3,916.25	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	36	18	-3.47	-19	-15	0.20	0.00
Invested Capital Turnover	7.30	8.39	-0.33	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	18	21	15	-3.21	-16	0.20	0.00
Enterprise Value (EV)	1,509	234	689	727	941	225	0.00
Market Capitalization	1,630	305	902	1,043	1,227	159	159
Book Value per Share	$1.35	$0.94	$3.44	$5.92	$6.20	($35.28)	$0.00
Tangible Book Value per Share	$1.27	$0.87	$3.32	$5.92	$6.20	($35.28)	$0.00
Total Capital	265	290	407	370	271	101	0.00
Total Debt	107	202	198	72	0.00	0.00	0.00
Total Long-Term Debt	107	202	198	72	0.00	0.00	0.00
Net Debt	-121	-71	-213	-316	-286	-101	0.00
Capital Expenditures (CapEx)	0.14	0.43	0.33	1.00	0.32	0.30	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	26	11	-11	-19	-16	-0.03	0.00
Debt-free Net Working Capital (DFNWC)	255	284	400	369	270	101	0.00
Net Working Capital (NWC)	255	284	400	369	270	101	0.00
Net Nonoperating Expense (NNE)	50	93	100	62	40	12	5.44
Net Nonoperating Obligations (NNO)	-121	-71	-213	-316	-286	-101	0.00
Total Depreciation and Amortization (D&A)	-4.30	-5.47	-1.32	3.91	0.19	-0.29	-0.01
Debt-free, Cash-free Net Working Capital to Revenue	13.35%	18.42%	-304.50%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	129.65%	476.06%	10,840.99%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	129.65%	476.06%	10,840.99%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.16)	$0.00	($5.66)	($4.18)	($3.80)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	120.96M	0.00	55.03M	49.41M	50.08M	0.00	0.00
Adjusted Diluted Earnings per Share	($1.16)	$0.00	($5.66)	($4.18)	($3.80)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	120.96M	0.00	55.03M	49.41M	50.08M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($3.80)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	118.64M	0.00	61.08M	50.38M	35.67M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-90	-169	-211	-145	-96	-30	-14
Normalized NOPAT Margin	-45.73%	-283.14%	-5,728.13%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-79.15%	-434.57%	-8,449.76%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	-4.73	-7.72	-18.90	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-3.31	-5.68	-13.49	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-4.73	-7.73	-18.92	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-3.31	-5.69	-13.51	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Arcutis Biotherapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	32.84%	427.58%	17.44%	494.57%	1,682.42%	356.81%	5,156.41%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	32.54%	86.11%	0.52%	27.96%	61.33%	11.30%	65.81%	-0.16%	-21.29%	4.56%	-85.48%
EBIT Growth	20.96%	86.94%	-2.05%	29.53%	62.25%	10.25%	66.75%	2.70%	-16.92%	8.72%	-80.43%
NOPAT Growth	22.43%	87.52%	-5.86%	24.99%	58.54%	10.60%	64.77%	-1.42%	-21.77%	4.01%	-83.52%
Net Income Growth	29.17%	83.72%	7.21%	26.28%	55.83%	7.96%	58.44%	-5.32%	-24.53%	-0.97%	-89.03%
EPS Growth	37.50%	84.48%	54.79%	63.79%	75.57%	51.26%	61.38%	11.45%	-3.15%	17.36%	-65.79%
Operating Cash Flow Growth	3.87%	98.67%	21.14%	32.14%	60.67%	20.86%	35.03%	-7.27%	-41.02%	-37.43%	-65.58%
Free Cash Flow Firm Growth	-13.04%	62.74%	32.18%	28.69%	47.66%	-1.55%	18.26%	-161.80%	-266.17%	-34.93%	-34.84%
Invested Capital Growth	121.70%	104.59%	54.51%	154.53%	350.38%	609.07%	282.40%	171.76%	128.19%	81.30%	-83.43%
Revenue Q/Q Growth	-7.73%	59.45%	45.04%	-37.75%	0.00%	-64.51%	634.28%	86.62%	-6.08%	308.41%	0.00%
EBITDA Q/Q Growth	-136.11%	76.47%	25.04%	-61.98%	0.00%	-68.48%	45.72%	13.06%	-11.56%	35.06%	-59.02%
EBIT Q/Q Growth	-185.63%	78.12%	22.22%	-62.62%	0.00%	-70.94%	46.29%	12.89%	-12.22%	36.68%	-57.19%
NOPAT Q/Q Growth	-221.40%	80.46%	21.99%	-58.36%	0.00%	-65.75%	44.72%	12.46%	-11.46%	34.68%	-59.13%
Net Income Q/Q Growth	-132.30%	74.03%	20.63%	-47.91%	0.00%	-48.07%	36.94%	11.37%	-11.22%	33.14%	-59.79%
EPS Q/Q Growth	-122.22%	72.73%	21.43%	-31.25%	0.00%	20.55%	37.07%	11.45%	-10.08%	37.04%	-44.27%
Operating Cash Flow Q/Q Growth	-3,961.50%	97.84%	23.12%	-42.77%	0.00%	-27.87%	33.84%	17.25%	-13.06%	-4.98%	-9.22%
Free Cash Flow Firm Q/Q Growth	-90.81%	37.20%	26.38%	-28.15%	0.00%	-14.31%	22.59%	5.95%	-22.02%	7.99%	-147.95%
Invested Capital Q/Q Growth	42.57%	20.29%	10.63%	16.85%	0.00%	-9.16%	82.25%	106.76%	248.72%	67.45%	28.30%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	86.59%	90.32%	87.70%	88.77%	93.43%	83.39%	96.90%	85.05%	71.84%	83.62%	62.90%
EBITDA Margin	-29.65%	-11.59%	-78.53%	-151.94%	-58.39%	-440.03%	-92.70%	-1,253.95%	-2,691.69%	-2,266.09%	-14,252.28%
Operating Margin	-37.25%	-10.70%	-87.29%	-162.28%	-63.79%	-452.23%	-96.84%	-1,286.38%	-2,742.36%	-2,310.84%	-14,448.00%
EBIT Margin	-33.11%	-10.70%	-77.94%	-145.34%	-55.64%	-432.00%	-89.70%	-1,226.24%	-2,627.04%	-2,198.72%	-14,180.69%
Profit (Net Income) Margin	-38.06%	-15.12%	-92.81%	-169.59%	-71.38%	-490.05%	-117.47%	-1,367.84%	-2,880.26%	-2,432.25%	-14,856.41%
Tax Burden Percent	101.13%	40.50%	100.00%	100.00%	100.92%	100.14%	107.24%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	113.68%	349.03%	119.07%	116.69%	127.12%	113.28%	122.11%	111.55%	109.64%	110.62%	104.77%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-148.32%	-54.65%	0.00%	0.00%	0.00%	-2,656.30%	-756.22%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-142.93%	-48.98%	0.00%	0.00%	0.00%	-2,639.78%	-743.95%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	113.83%	38.27%	0.00%	0.00%	0.00%	2,514.03%	723.35%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-34.49%	-16.38%	0.00%	0.00%	0.00%	-142.27%	-32.87%	-239.82%	-166.32%	-122.80%	-98.07%
Cash Return on Invested Capital (CROIC)	-302.60%	-402.47%	-42.84%	-87.17%	-127.32%	-1,074.23%	-1,048.10%	-2,312.02%	-4,727.41%	0.00%	0.00%
Operating Return on Assets (OROA)	-17.13%	-6.09%	0.00%	0.00%	0.00%	-65.14%	-10.97%	-46.03%	-45.70%	-18.90%	-22.95%
Return on Assets (ROA)	-19.69%	-8.61%	0.00%	0.00%	0.00%	-73.89%	-14.37%	-51.34%	-50.10%	-20.91%	-24.04%
Return on Common Equity (ROCE)	-34.49%	-16.38%	0.00%	0.00%	0.00%	-142.27%	-32.87%	-239.82%	-166.32%	-122.80%	-98.07%
Return on Equity Simple (ROE_SIMPLE)	-90.93%	0.00%	0.00%	0.00%	0.00%	0.00%	-573.40%	-410.91%	-234.19%	0.00%	-114.77%
Net Operating Profit after Tax (NOPAT)	-17	-5.34	-27	-35	-22	-43	-26	-47	-53	-48	-73
NOPAT Margin	-26.08%	-7.49%	-61.10%	-113.60%	-44.66%	-316.56%	-67.79%	-900.46%	-1,919.65%	-1,617.59%	-10,113.60%
Net Nonoperating Expense Percent (NNEP)	-5.39%	-5.66%	-18.45%	-15.09%	-7.88%	-16.52%	-12.27%	-17.32%	-13.14%	-9.11%	-10.58%
Return On Investment Capital (ROIC_SIMPLE)	-6.86%	-2.02%	-	-	-	-14.74%	-	-	-	-11.76%	-
Cost of Revenue to Revenue	13.41%	9.68%	12.30%	11.23%	6.57%	16.61%	3.10%	14.95%	28.16%	16.38%	37.10%
SG&A Expenses to Revenue	97.20%	80.73%	131.42%	188.52%	110.54%	359.86%	124.89%	885.51%	1,543.26%	1,250.35%	4,892.83%
R&D to Revenue	26.64%	20.29%	43.57%	62.54%	46.68%	175.77%	68.84%	485.92%	1,270.95%	1,144.11%	9,618.07%
Operating Expenses to Revenue	123.84%	101.02%	174.99%	251.06%	157.23%	535.63%	193.74%	1,371.43%	2,814.20%	2,385.38%	14,548.00%
Earnings before Interest and Taxes (EBIT)	-22	-7.63	-35	-45	-28	-58	-34	-64	-73	-65	-103
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-20	-8.27	-35	-47	-29	-60	-35	-65	-75	-67	-103
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	13.01	10.35	6.94	5.78	4.16	3.44	0.00	7.27	4.81	4.30	3.64
Price to Tangible Book Value (P/TBV)	14.71	11.01	7.40	5.97	4.28	3.71	0.00	7.94	5.06	4.46	3.74
Price to Revenue (P/Rev)	8.72	8.30	0.00	0.00	0.00	5.11	0.00	50.21	103.90	244.64	1,359.12
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	34.21	41.72	31.94	33.75	31.54	13.23	0.00	48.27	104.04	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	8.29	7.68	0.00	0.00	0.00	3.92	0.00	44.22	83.09	186.84	970.92
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.75	0.68	1.31	1.09	0.90	2.28	4.30	2.48	1.42	0.94	0.73
Long-Term Debt to Equity	0.75	0.68	0.67	1.09	0.90	2.28	4.30	2.48	1.42	0.94	0.73
Financial Leverage	-0.80	-0.78	-0.76	-0.86	-0.92	-0.95	-0.97	-1.02	-1.03	-1.04	-1.03
Leverage Ratio	2.24	2.80	3.59	2.87	2.35	2.65	2.53	2.25	1.89	1.69	1.41
Compound Leverage Factor	2.54	9.79	4.28	3.35	2.99	3.00	3.08	2.51	2.07	1.87	1.48
Debt to Total Capital	43.00%	40.49%	56.64%	52.23%	47.41%	69.47%	81.12%	71.28%	58.72%	48.55%	42.08%
Short-Term Debt to Total Capital	0.00%	0.00%	27.55%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	43.00%	40.49%	29.09%	52.23%	47.41%	69.47%	81.12%	71.28%	58.72%	48.55%	42.08%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	57.00%	59.51%	43.36%	47.77%	52.59%	30.53%	18.88%	28.72%	41.28%	51.45%	57.92%
Debt to EBITDA	-0.88	-0.81	0.00	0.00	0.00	-0.86	-0.83	-0.64	-0.64	-0.67	-0.66
Net Debt to EBITDA	0.75	0.91	0.00	0.00	0.00	0.30	0.11	0.23	0.43	0.72	0.94
Long-Term Debt to EBITDA	-0.88	-0.81	0.00	0.00	0.00	-0.86	-0.83	-0.64	-0.64	-0.67	-0.66
Debt to NOPAT	-1.27	-1.19	0.00	0.00	0.00	-1.20	-1.15	-0.90	-0.90	-0.94	-0.92
Net Debt to NOPAT	1.07	1.35	0.00	0.00	0.00	0.42	0.16	0.32	0.61	1.01	1.32
Long-Term Debt to NOPAT	-1.27	-1.19	0.00	0.00	0.00	-1.20	-1.15	-0.90	-0.90	-0.94	-0.92
Altman Z-Score	2.08	1.98	-0.81	-0.17	0.10	-2.70	0.00	-1.94	-0.84	0.61	1.12
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.55	4.15	2.46	8.46	9.89	7.08	6.72	8.43	9.93	11.57	13.39
Quick Ratio	3.11	3.72	2.27	7.90	9.32	6.38	5.89	7.80	9.32	11.06	12.92
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-45	-24	-38	-52	-40	-64	-56	-72	-77	-63	-68
Operating Cash Flow to CapEx	-4,996.71%	0.00%	-24,257.34%	0.00%	0.00%	-937,400.00%	-68,725.00%	-24,088.77%	-97,980.49%	-57,776.42%	-1,128,250.00%
Free Cash Flow to Firm to Interest Expense	-15.25	-4.29	-5.71	-6.89	-5.38	-8.24	-7.40	-9.84	-10.92	-9.11	-13.98
Operating Cash Flow to Interest Expense	-10.19	-0.13	-5.21	-6.03	-4.23	-7.25	-5.82	-9.05	-11.41	-10.28	-13.82
Operating Cash Flow Less CapEx to Interest Expense	-10.39	-0.13	-5.24	-6.03	-4.23	-7.25	-5.83	-9.08	-11.42	-10.29	-13.82
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.52	0.57	0.00	0.00	0.00	0.15	0.12	0.04	0.02	0.01	0.00
Accounts Receivable Turnover	3.47	3.98	0.00	0.00	0.00	3.48	4.49	0.00	0.00	0.00	0.00
Inventory Turnover	1.65	1.38	0.00	0.00	0.00	0.48	0.35	0.00	0.00	0.00	0.00
Fixed Asset Turnover	148.56	152.36	0.00	0.00	0.00	34.86	26.70	5.91	3.06	1.78	0.36
Accounts Payable Turnover	1.32	1.46	0.00	0.00	0.00	0.48	0.30	0.18	0.12	0.09	0.04
Days Sales Outstanding (DSO)	105.11	91.81	0.00	0.00	0.00	104.91	81.30	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	220.62	263.90	0.00	0.00	0.00	755.62	1,030.73	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	277.04	250.09	0.00	0.00	0.00	761.87	1,235.81	2,019.34	2,962.63	3,916.25	9,184.02
Cash Conversion Cycle (CCC)	48.68	105.62	0.00	0.00	0.00	98.65	-123.77	-2,019.34	-2,962.63	-3,916.25	-9,184.02
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	52	36	30	27	23	18	19	11	5.17	-3.47	-11
Invested Capital Turnover	5.69	7.30	0.00	0.00	0.00	8.39	11.16	-5.55	-0.98	-0.33	-0.09
Increase / (Decrease) in Invested Capital	28	18	11	17	18	21	30	26	23	15	-4.85
Enterprise Value (EV)	1,764	1,509	961	917	734	234	0.00	516	537	689	704
Market Capitalization	1,856	1,630	1,087	1,077	935	305	0.00	585	672	902	985
Book Value per Share	$1.20	$1.35	$1.34	$1.61	$2.03	$0.94	$0.76	$1.31	$2.29	$3.44	$5.25
Tangible Book Value per Share	$1.06	$1.27	$1.26	$1.56	$1.97	$0.87	$0.65	$1.20	$2.17	$3.32	$5.11
Total Capital	250	265	361	390	428	290	248	280	338	407	468
Total Debt	108	107	205	204	203	202	201	200	199	198	197
Total Long-Term Debt	108	107	105	204	203	202	201	200	199	198	197
Net Debt	-91	-121	-127	-159	-202	-71	-27	-70	-135	-213	-281
Capital Expenditures (CapEx)	0.61	0.00	0.14	0.00	0.00	0.01	0.06	0.28	0.08	0.12	0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	34	26	20	20	16	11	12	2.61	-2.68	-11	-19
Debt-free Net Working Capital (DFNWC)	233	255	351	383	421	284	240	272	331	400	460
Net Working Capital (NWC)	233	255	251	383	421	284	240	272	331	400	460
Net Nonoperating Expense (NNE)	7.89	5.45	14	17	13	23	19	24	27	24	34
Net Nonoperating Obligations (NNO)	-91	-121	-127	-159	-202	-71	-27	-70	-135	-213	-281
Total Depreciation and Amortization (D&A)	2.27	-0.64	-0.26	-2.04	-1.37	-1.09	-1.15	-1.44	-1.80	-2.00	-0.52
Debt-free, Cash-free Net Working Capital to Revenue	15.90%	13.35%	0.00%	0.00%	0.00%	18.42%	23.70%	22.42%	-41.43%	-304.50%	-2,562.76%
Debt-free Net Working Capital to Revenue	109.27%	129.65%	0.00%	0.00%	0.00%	476.06%	488.69%	2,335.15%	5,112.90%	10,840.99%	63,395.45%
Net Working Capital to Revenue	109.27%	129.65%	0.00%	0.00%	0.00%	476.06%	488.69%	2,335.15%	5,112.90%	10,840.99%	63,395.45%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.20)	($0.09)	($0.33)	($0.42)	($0.32)	($0.58)	($0.73)	($1.16)	($1.31)	($1.19)	($1.89)
Adjusted Weighted Average Basic Shares Outstanding	126.04M	120.96M	124.30M	123.48M	111.05M	69.31M	61.73M	61.43M	61.17M	55.03M	57.09M
Adjusted Diluted Earnings per Share	($0.20)	($0.09)	($0.33)	($0.42)	($0.32)	($0.58)	($0.73)	($1.16)	($1.31)	($1.19)	($1.89)
Adjusted Weighted Average Diluted Shares Outstanding	126.04M	120.96M	124.30M	123.48M	111.05M	69.31M	61.73M	61.43M	61.17M	55.03M	57.09M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	119.20M	118.64M	117.04M	116.89M	115.76M	0.00	94.38M	61.65M	61.42M	61.08M	60.93M
Normalized Net Operating Profit after Tax (NOPAT)	-17	-5.34	-27	-35	-22	-43	-26	-47	-53	-48	-73
Normalized NOPAT Margin	-26.08%	-7.49%	-61.10%	-113.60%	-44.66%	-316.56%	-67.79%	-900.46%	-1,919.65%	-1,617.59%	-10,113.60%
Pre Tax Income Margin	-37.63%	-37.33%	-92.81%	-169.59%	-70.73%	-489.38%	-109.53%	-1,367.84%	-2,880.26%	-2,432.25%	-14,856.41%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-7.31	-1.37	-5.24	-5.99	-3.69	-7.53	-4.52	-8.66	-10.37	-9.41	-20.99
NOPAT to Interest Expense	-5.76	-0.96	-4.11	-4.68	-2.96	-5.52	-3.42	-6.36	-7.58	-6.93	-14.97
EBIT Less CapEx to Interest Expense	-7.51	-1.37	-5.26	-5.99	-3.69	-7.53	-4.53	-8.70	-10.39	-9.43	-20.99
NOPAT Less CapEx to Interest Expense	-5.96	-0.96	-4.13	-4.68	-2.96	-5.52	-3.43	-6.40	-7.59	-6.94	-14.97
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Arcutis Biotherapeutics' Financials

When does Arcutis Biotherapeutics's fiscal year end?

According to the most recent income statement we have on file, Arcutis Biotherapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Arcutis Biotherapeutics' net income changed over the last 6 years?

Arcutis Biotherapeutics' net income appears to be on an upward trend, with a most recent value of -$140.04 million in 2024, rising from -$19.26 million in 2018. The previous period was -$262.14 million in 2023. View Arcutis Biotherapeutics' forecast to see where analysts expect Arcutis Biotherapeutics to go next.

What is Arcutis Biotherapeutics's operating income?

Arcutis Biotherapeutics's total operating income in 2024 was -$128.40 million, based on the following breakdown:

Total Gross Profit: $177.41 million
Total Operating Expenses: $305.81 million

How has Arcutis Biotherapeutics revenue changed over the last 6 years?

Over the last 6 years, Arcutis Biotherapeutics' total revenue changed from $0.00 in 2018 to $196.54 million in 2024, a change of 19,654,200,000.0%.

How much debt does Arcutis Biotherapeutics have?

Arcutis Biotherapeutics' total liabilities were at $191.35 million at the end of 2024, a 24.3% decrease from 2023, and a 3,347.7% increase since 2019.

How much cash does Arcutis Biotherapeutics have?

In the past 5 years, Arcutis Biotherapeutics' cash and equivalents has ranged from $53.64 million in 2022 to $96.45 million in 2021, and is currently $71.34 million as of their latest financial filing in 2024.

How has Arcutis Biotherapeutics' book value per share changed over the last 6 years?

Over the last 6 years, Arcutis Biotherapeutics' book value per share changed from 0.00 in 2018 to 1.35 in 2024, a change of 134.6%.

Related Companies

This page (NASDAQ:ARQT) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcutis Biotherapeutics (ARQT) Financials

Frequently Asked Questions About Arcutis Biotherapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcutis Biotherapeutics (ARQT) Financials

Annual Income Statements for Arcutis Biotherapeutics

Quarterly Income Statements for Arcutis Biotherapeutics

Annual Cash Flow Statements for Arcutis Biotherapeutics

Quarterly Cash Flow Statements for Arcutis Biotherapeutics

Annual Balance Sheets for Arcutis Biotherapeutics

Quarterly Balance Sheets for Arcutis Biotherapeutics

Annual Metrics And Ratios for Arcutis Biotherapeutics

Quarterly Metrics And Ratios for Arcutis Biotherapeutics

Frequently Asked Questions About Arcutis Biotherapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools